MolDX: Breast Cancer Index® (BCI) Gene Expression Test

The BCI gene expression test is covered only for postmenopausal women with invasive ER+ and/or PR+ and HER2- early-stage breast cancer (T1-T3, pN0-pN1, M0) who have no distant metastasis, when results will be used to guide chemotherapy decisions and/or evaluate late recurrence risk and endocrine therapy extension. Coverage is restricted to this population and clinical use; tests for patients who are premenopausal, HER2+, ER/PR-negative, metastatic (M1), or whose clinical documentation does not show intended use to inform treatment are not covered.

"Patient is postmenopausal woman."

Sign up to see full coverage criteria, indications, and limitations.